Non-invasive prenatal testing (NIPT) is a blood test performed during pregnancy to screen for certain genetic conditions affecting the baby. The test analyses small fragments of placental DNA circulating in the mother’s bloodstream, and because it only requires a blood sample from the mother, it poses no physical risk to the pregnancy. 

In pregnancy, NIPT is most commonly used to screen for the genetic conditions caused by an extra copy of a chromosome (trisomy), including Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18) and Patau syndrome (Trisomy 13). More advanced forms of NIPT are also available that can screen for additional genetic conditions, including certain microdeletions (small missing sections of chromosomes) and, in some tests, rarer conditions caused by changes in single genes. 

The main advantage of NIPT is that it is a highly accurate screening test, detecting the common trisomies with greater than 99% sensitivity for Down syndrome, while avoiding the small miscarriage risk associated with invasive diagnostic tests. However, it is important to remember that NIPT is a screening test rather than a diagnostic test, and any high-risk result may require confirmation with further testing.

Non-invasive prenatal testing (NIPT) is primarily used to screen for chromosomal conditions that can affect the baby during pregnancy. A standard NIPT screens for the most common chromosomal conditions caused by an extra copy of a chromosome, known as trisomies, including:

• Down syndrome (Trisomy 21)
• Edwards syndrome (Trisomy 18)
• Patau syndrome (Trisomy 13)

Many NIPT tests also include screening for sex chromosome conditions, such as:

• Turner syndrome (Monosomy X)
• Klinefelter syndrome (XXY)
• Jacobs syndrome (XYY)
• Triple X syndrome (XXX)

More advanced NIPT panels can also screen for selected microdeletion syndromes, which occur when a small section of a chromosome is missing. Examples commonly included in expanded panels include:

• 2 deletion syndrome (DiGeorge syndrome)
• 5p deletion syndrome (Cri-du-Chat syndrome)
• 4p deletion syndrome (Wolf–Hirschhorn syndrome)
• 1p36 deletion syndrome
• 2 deletion syndromes (Prader–Willi / Angelman region)
• 11q deletion syndrome (Jacobsen syndrome)

Some specialised laboratories also offer expanded panels that include selected single-gene disorders, although these tests are more specialised and are usually considered in specific clinical circumstances.

At The Pregnancy Clinic, we offer the full range of NIPT options. An essential part of this process is careful pre-test counselling, which helps determine the most appropriate type of NIPT for your circumstances. Post-test counselling is also provided so that results are interpreted clearly and meaningfully, ensuring that you understand what the results mean and what the next steps may be if further assessment is required.

NIPT is the most accurate screening test currently available for the common chromosomal conditions in pregnancy. It detects more than 99% of babies with Down syndrome, with a very low false-negative rate (less than 1%) and a false-positive rate of around 0.1–0.3%. In comparison, traditional first-trimester combined screening detects about 85–90% of Down syndrome cases, meaning around 10–15% may be missed.

NIPT is also a very effective screening test for sex chromosome conditions such as Turner, Klinefelter, XYY and Triple X syndromes, with detection rates generally above 95–99% depending on the condition.

Some expanded NIPT panels can also screen for microdeletion syndromes (such as DiGeorge syndrome) and selected single-gene conditions, although the accuracy for these rarer conditions is less well established than for the common trisomies.

Overall, NIPT provides very high screening accuracy for the most common chromosomal conditions, but it remains a screening test rather than a diagnostic test, so any high-risk result usually requires confirmation with diagnostic testing.

No. NIPT screens for a limited number of relatively common genetic conditions, most commonly the trisomies such as Down syndrome, Edwards syndrome and Patau syndrome, and in some cases certain sex chromosome conditions or selected microdeletions.

While NIPT is extremely effective at screening for these specific conditions, there are hundreds of other rare genetic conditions that it does not assess. A normal (low-risk) NIPT result therefore does not exclude all possible genetic or developmental conditions.

For this reason, detailed ultrasound assessment remains an essential part of pregnancy care. Scans such as the Nuchal scan at 12 weeks and the Anomaly scan at 20 weeks evaluate the baby’s anatomy and development in detail. These scans can sometimes identify findings that may be associated with a wider range of genetic conditions that are not detectable by NIPT.

If ultrasound findings raise concerns, further investigations may be recommended. These may include diagnostic tests such as amniocentesis or chorionic villus sampling, with advanced genetic analysis such as chromosomal microarray testing or whole exome sequencing, which can assess a much broader range of genetic conditions.

For this reason, NIPT and detailed ultrasound scans are complementary, and both play an important role in providing a comprehensive assessment of pregnancy health.

No. NIPT is a screening test, not a diagnostic test. It estimates the chance that the baby may have certain genetic conditions but does not provide a definitive diagnosis.

A low-risk result is very reassuring and makes the screened conditions highly unlikely, but it does not completely exclude them. There are also many other genetic conditions that NIPT does not assess, as it screens only for a limited number of relatively common chromosomal abnormalities.

A high-risk result does not confirm that the baby has the condition. It indicates that the chance is increased and therefore requires confirmation with diagnostic testing, such as chorionic villus sampling (CVS) or amniocentesis, which analyse the baby’s genetic material directly.

The limitations of NIPT are particularly relevant when screening for microdeletions or rarer genetic changes, where detection rates and accuracy are lower than for the common trisomies. For this reason, NIPT should be considered complementary to detailed ultrasound assessment, rather than a replacement for it.

Detailed scans such as the Nuchal scan at 12 weeks and the Anomaly scan at 20 weeks remain essential because they assess the baby’s development and can identify findings associated with a much wider range of genetic conditions that may then be investigated with diagnostic genetic testing if required.

Specialist counselling before and after the NIPT is important because it helps ensure that the most appropriate test is chosen and that the results are interpreted correctly within the context of your pregnancy. At The Pregnancy Clinic, NIPT is always supported by both pre-test and post-test consultation with a fetal medicine specialist.

Pre-test counselling is important because it allows discussion of:

• Whether NIPT is appropriate for your individual pregnancy, particularly in the context of previous pregnancy history or ultrasound findings
• Which type of NIPT panel may be most suitable, as different tests screen for different conditions
• What the test can and cannot detect, including its limitations
• How NIPT complements ultrasound assessment, rather than replacing it

Post-test counselling is equally important to ensure that the results are interpreted accurately and meaningfully. This discussion helps explain:

• What a low-risk result means and its reassuring implications
• What a high-risk result means and the need for confirmatory diagnostic testing, such as chorionic villus sampling (CVS) or amniocentesis
• How the results should be interpreted alongside ultrasound findings and overall pregnancy risk

For these reasons, NIPT is best offered as part of a consultant-led assessment, where appropriate counselling ensures that testing is used safely and that families are supported in understanding both the benefits and limitations of the test.

Yes. A low-risk NIPT result is reassuring, but it does not replace the need for detailed ultrasound scans during pregnancy.

NIPT is designed to screen for certain genetic conditions, such as Down syndrome, Edwards syndrome and Patau syndrome, and in some tests selected sex chromosome conditions or microdeletions. However, it does not assess how the baby is developing structurally and does not evaluate the placenta or many other aspects of pregnancy health.

There are hundreds of genetic and developmental conditions that NIPT does not screen for. Many important conditions affecting the brain, heart, spine and other organs are detected only through detailed ultrasound assessment.

For this reason, scans such as the Nuchal scan at 12 weeks and the Anomaly scan at 20 weeks remain essential parts of pregnancy care. These scans assess the baby’s anatomy, development and placental function, and can sometimes identify findings associated with genetic conditions that may require further investigation with diagnostic tests such as chorionic villus sampling (CVS) or amniocentesis.

In this way, NIPT and ultrasound scans are complementary. NIPT provides highly accurate screening for certain chromosomal conditions, while ultrasound remains the main method for assessing the baby’s development and overall pregnancy wellbeing.

NIPT can usually be performed from 10 weeks of pregnancy onwards, when there is sufficient placental DNA circulating in the mother’s bloodstream for reliable analysis.

An ultrasound scan before the test is an important part of the assessment. The scan confirms the gestational age, fetal growth and overall development of the pregnancy, and ensures that the timing of the test is appropriate. Performing NIPT too early in pregnancy may result in insufficient placental DNA in the maternal blood, which can lead to an inconclusive result or the need for repeat testing.

In some circumstances, testing for the baby’s sex can be performed earlier, typically from around 7 weeks of pregnancy, although this depends on the specific test used.

Your consultant will advise on the most appropriate timing for NIPT based on the ultrasound findings, gestational age and your individual screening pathway, ensuring that the test is performed at the time when it is most likely to provide a reliable result.

Results are typically available within 5–7 working days from the blood sample being taken.

In a small proportion of cases, usually around 3–4%, NIPT may not provide a result. This is most commonly due to low levels of placental DNA (fetal fraction) in the mother’s blood at the time of testing.

There can be several reasons for a failed or inconclusive test, including testing too early in pregnancy, naturally low fetal fraction, higher maternal weight, certain technical factors in the sample, or rarely other biological reasons. Importantly, a failed result does not necessarily mean that there is a problem with the pregnancy. If this occurs:

• The test can often be repeated at a later stage of pregnancy, when placental DNA levels may be higher
• Your consultant may discuss alternative screening options
• In some situations, diagnostic testing may be considered depending on the clinical context

This possibility and the appropriate next steps are discussed during the consultation before testing, so that you are fully informed about how results are interpreted and managed.

All NIPT results at The Pregnancy Clinic are reviewed and explained by a Consultant in Fetal–Maternal Medicine. The results are interpreted in the context of your ultrasound findings, gestational age, and overall screening pathway, ensuring that they are understood clearly and meaningfully.

During the discussion, your consultant will explain what the result means, the degree of reassurance it provides, and the limitations of the test. If the result indicates a low chance, this will be discussed alongside the role of ongoing ultrasound scans in monitoring the baby’s development.

If the result indicates a higher chance, or if the test result is inconclusive, your consultant will explain the possible reasons and discuss the appropriate next steps, which may include repeat testing or diagnostic tests such as chorionic villus sampling (CVS) or amniocentesis.

This consultant-led counselling ensures that results are interpreted safely and that you receive clear guidance and support in deciding the most appropriate plan for your pregnancy.